Zepbound (tirzepatide) is a prescription medication approved by the FDA for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbid condition
A new pharmacological approach: The incretin effect First of all, it should be noted that although they are best known to the public by their trade names (Ozempic, Mounjaro), it is the generic names of these drugs (semaglutide and tirzepatide, respectively) that are used in the scientific literature and we will therefore use this nomenclature throughout this article
However, it's essential to consult your healthcare provider to ensure these medications are appropriate for your specific situation
I will wait for results of the CVOT and wouldnt bet on a benefit yet
It's one of the FDA approved peptides for weight loss 2026, alongside semaglutide (Wegovy) and liraglutide (Saxenda), and represents the current standard for next-generation incretin-based therapies, with clinical data showing superior weight loss compared to single-agonist GLP-1 drugs
Ready to give semaglutide a try
